• Dominic O Co.
• Division of Allergy, Immunology, Rheumatology, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Clinical Science Center (CSC), H6/572, 600 Highland Avenue, Madison, WI 53792, USA. Electronic address: doco@wisc.edu.
• Med. Clin. North Am. 2024 Jan 1; 108 (1): 9310593-105.

AbstractAcquired demyelinating syndromes (ADS) are a heterogenous group of inflammatory demyelinating conditions that include presentations of optic neuritis, transverse myelitis, and acute demyelinating encephalomyelitis. They can be monophasic or can develop into relapsing episodes of the initial demyelinating event or evolve to include other types of demyelination. Significant progress has been made in differentiating subtypes of ADS that differ in their tendency to relapse and in which anti-inflammatory therapies are effective. Differentiating between these subtypes is important for the optimal management of these patients. Clinical features, labs (especially autoantibodies), and MRI findings can help to differentiate between the different ADS.Copyright © 2023 Elsevier Inc. All rights reserved.

12 keywords...

hide…